Papp K - Search Results

1

Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: Results from two phase 3 studies.

Papp K, Szepietowski JC, Kircik L, Toth D, Eichenfield LF, Forman SB, Kuligowski ME, Kallender H, Sun K, Ren H, Simpson EL. Papp K, et al. J Am Acad Dermatol. 2023 May;88(5):1008-1016. doi: 10.1016/j.jaad.2022.09.060. Epub 2022 Nov 26. J Am Acad Dermatol. 2023. PMID: 36574595 Free article. Clinical Trial.

2

The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody.

Papp K, Bissonnette R, Krueger JG, Carey W, Gratton D, Gulliver WP, Lui H, Lynde CW, Magee A, Minier D, Ouellet JP, Patel P, Shapiro J, Shear NH, Kramer S, Walicke P, Bauer R, Dedrick RL, Kim SS, White M, Garovoy MR. Papp K, et al. J Am Acad Dermatol. 2001 Nov;45(5):665-74. doi: 10.1067/mjd.2001.117850. J Am Acad Dermatol. 2001. PMID: 11606914 Clinical Trial.

3

Validation of the Eczema Area and Severity Index for atopic dermatitis in a cohort of 1550 patients from the pimecrolimus cream 1% randomized controlled clinical trials programme.

Barbier N, Paul C, Luger T, Allen R, De Prost Y, Papp K, Eichenfield LF, Cherill R, Hanifin J. Barbier N, et al. Among authors: papp k. Br J Dermatol. 2004 Jan;150(1):96-102. doi: 10.1111/j.1365-2133.2004.05696.x. Br J Dermatol. 2004. PMID: 14746622 Clinical Trial.

4

Efficacy and safety of adalimumab when added to inadequate therapy for the treatment of psoriasis: results of PRIDE, an open-label, multicentre, phase IIIb study.

Papp K, Ho V, Teixeira HD, Guerette B, Chen K, Lynde C. Papp K, et al. J Eur Acad Dermatol Venereol. 2012 Aug;26(8):1007-13. doi: 10.1111/j.1468-3083.2011.04225.x. Epub 2011 Oct 25. J Eur Acad Dermatol Venereol. 2012. PMID: 22023702 Clinical Trial.

5

Long-term outcomes of interruption and retreatment vs. continuous therapy with adalimumab for psoriasis: subanalysis of REVEAL and the open-label extension study.

Papp K, Menter A, Poulin Y, Gu Y, Sasso EH. Papp K, et al. J Eur Acad Dermatol Venereol. 2013 May;27(5):634-42. doi: 10.1111/j.1468-3083.2012.04515.x. Epub 2012 Mar 16. J Eur Acad Dermatol Venereol. 2013. PMID: 22429586 Clinical Trial.

6

Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE).

Blauvelt A, Prinz JC, Gottlieb AB, Kingo K, Sofen H, Ruer-Mulard M, Singh V, Pathan R, Papavassilis C, Cooper S; FEATURE Study Group. Blauvelt A, et al. Br J Dermatol. 2015 Feb;172(2):484-93. doi: 10.1111/bjd.13348. Epub 2014 Dec 11. Br J Dermatol. 2015. PMID: 25132411 Clinical Trial.

7

Granulocyte-macrophage colony-stimulating factor (GM-CSF) as a therapeutic target in psoriasis: randomized, controlled investigation using namilumab, a specific human anti-GM-CSF monoclonal antibody.

Papp KA, Gooderham M, Jenkins R, Vender R, Szepietowski JC, Wagner T, Hunt B, Souberbielle B; NEPTUNE investigators. Papp KA, et al. Br J Dermatol. 2019 Jun;180(6):1352-1360. doi: 10.1111/bjd.17195. Epub 2018 Nov 2. Br J Dermatol. 2019. PMID: 30207587 Free PMC article. Clinical Trial.

8

Sustained long-term efficacy and safety of adalimumab in paediatric patients with severe chronic plaque psoriasis from a randomized, double-blind, phase III study.

Thaçi D, Papp K, Marcoux D, Weibel L, Pinter A, Ghislain PD, Landells I, Hoeger PH, Unnebrink K, Seyger MMB, Williams DA, Rubant S, Philipp S. Thaçi D, et al. Among authors: papp k. Br J Dermatol. 2019 Dec;181(6):1177-1189. doi: 10.1111/bjd.18029. Epub 2019 Jul 25. Br J Dermatol. 2019. PMID: 31017657 Free PMC article. Clinical Trial.

9

Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies.

Kimball AB, Papp KA, Reich K, Gooderham M, Li Q, Cichanowitz N, La Rosa C, Blauvelt A. Kimball AB, et al. Among authors: papp ka. Br J Dermatol. 2020 Jun;182(6):1359-1368. doi: 10.1111/bjd.18484. Epub 2019 Nov 19. Br J Dermatol. 2020. PMID: 31487406 Free PMC article. Clinical Trial.

10

Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II Study.

Lebwohl MG, Blauvelt A, Menter A, Papp KA, Guenthner S, Pillai R, Israel RJ, Jacobson A. Lebwohl MG, et al. Am J Clin Dermatol. 2019 Dec;20(6):863-871. doi: 10.1007/s40257-019-00466-2. Am J Clin Dermatol. 2019. PMID: 31493163 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

706 results

Search Page